Abstract
This review evaluates dose-response and comparative studies with inhaled corticosteroids (ICS) in asthma. A dose-response relationship for lung function variables has been demonstrated for some ICS, but not for all. Measurements of anti-inflammatory properties, e.g. bronchial challenge with adenosine 6-monophosphate, may provide better possibilities to detect dose-response relationships and differences between ICS. Studies with the same ICS delivered by different inhalers with different lung deposition characteristics show that efficacy is strongly related to the amount of drug deposited in the airways. Comparative studies with different ICS using different inhalers have often used doses resulting in effects at the top of the dose-response curve. However, a lack of statistically significant difference between treatments does not mean therapeutic equivalence. Comparative clinical studies should be performed with dose-response curves of both products and the relative dose ratio should be estimated. The minimum criterion is to use one dose of one product and fit the result of that treatment to a dose-response curve of the other. Down titration represents an alternative, clinically reliable study design. Clinically relevant differences between doses and treatments should be defined prior to the study; a proper power calculation has to be performed; and comparisons should be made on the dose scale rather than the effect scale.
Keywords: Asthma, comparative studies, dose scale, dose-response, down titration, single-dose comparison
Current Drug Therapy
Title: Some Aspects on Comparative Efficacy Studies with Inhaled Corticosteroids in Asthma
Volume: 2 Issue: 1
Author(s): Olof Selroos
Affiliation:
Keywords: Asthma, comparative studies, dose scale, dose-response, down titration, single-dose comparison
Abstract: This review evaluates dose-response and comparative studies with inhaled corticosteroids (ICS) in asthma. A dose-response relationship for lung function variables has been demonstrated for some ICS, but not for all. Measurements of anti-inflammatory properties, e.g. bronchial challenge with adenosine 6-monophosphate, may provide better possibilities to detect dose-response relationships and differences between ICS. Studies with the same ICS delivered by different inhalers with different lung deposition characteristics show that efficacy is strongly related to the amount of drug deposited in the airways. Comparative studies with different ICS using different inhalers have often used doses resulting in effects at the top of the dose-response curve. However, a lack of statistically significant difference between treatments does not mean therapeutic equivalence. Comparative clinical studies should be performed with dose-response curves of both products and the relative dose ratio should be estimated. The minimum criterion is to use one dose of one product and fit the result of that treatment to a dose-response curve of the other. Down titration represents an alternative, clinically reliable study design. Clinically relevant differences between doses and treatments should be defined prior to the study; a proper power calculation has to be performed; and comparisons should be made on the dose scale rather than the effect scale.
Export Options
About this article
Cite this article as:
Selroos Olof, Some Aspects on Comparative Efficacy Studies with Inhaled Corticosteroids in Asthma, Current Drug Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488507779422392
DOI https://dx.doi.org/10.2174/157488507779422392 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone
Recent Patents on Anti-Cancer Drug Discovery Enteric Coated Guar Gum Microspheres of Ornidazole for Colonic Delivery
Current Nanoscience Transient Left Ventricular Acute Failure after Cocaine Use
Current Drug Research Reviews Self-Assembled Amphotericin B Pharmacosome-Like Vesicles Derived from Lipid-Based Microtubes: A Model Carrier to Further Explore
Micro and Nanosystems Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD: Systematic Review and Meta-analysis
Current Drug Targets QSAR Study on 5-Lipoxygenase Activating Protein (FLAP) Inhibitors: The Derivatives of 2,2-Bisaryl-Bicycloheptane
Letters in Drug Design & Discovery Cellular Signaling Crosstalk Between Multiple Receptors for Investigation of Pathophysiology in Multifactorial Diseases - What is Clinically-Relevant Crosstalk?
Current Medicinal Chemistry Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: N-Acetyltransferases: Lessons Learned from Eighty Years of Research (Guest Editor: Jose A.G. Agundez) ]
Current Drug Metabolism Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Inflammatory Cells and Oxygen Radicals
Current Drug Targets - Inflammation & Allergy Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Patented Herbal Formulations and their Therapeutic Applications
Recent Patents on Drug Delivery & Formulation New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook
Current Drug Delivery Current Anti-Inflammatory Therapies and the Potential of Secretory Phospholipase A2 Inhibitors in the Design of New Anti-Inflammatory Drugs: A Review of 2012 - 2018
Current Medicinal Chemistry Homogeneous Time Resolved Fluorescence Assay to Measure Histamine Release
Combinatorial Chemistry & High Throughput Screening Heme Oxygenase-1: A Novel Therapeutic Target in Oxidative Tissue Injuries
Current Medicinal Chemistry Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued)